全球甲状腺疾病治疗市场规模、份额、成长分析、治疗方法、最终用户 - 2024-2031 年产业预测

Global Thyroid Gland Disorders Treatment Market Size, Share, Growth Analysis, By Treatment Methods(Medication, Radioiodine therapy), By End-users(Hospitals, Clinics) - Industry Forecast 2024-2031

出版日期: 2024年02月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

在预测期内（2024-2031年），全球甲状腺疾病治疗市场规模将于2022年达到23.7亿美元，从2023年的24.5亿美元增长到2031年的31.4亿美元，预计将以复合年增长率增长2019 年为3.17%。

近年来，全球甲状腺疾病治疗市场显着成长，这主要是由于甲状腺功能亢进等疾病在全球的盛行率不断增加。人口老化、医疗技术的进步以及对早期诊断和治疗的日益重视等因素导致了这种扩张。此外，针对特定甲状腺问题的新客製化医疗技术和标靶药物的推出正在丰富市场格局。由于甲状腺疾病的高盛行率和高昂的医疗费用，北美和欧洲目前在该市场占据主导地位，但拉丁美洲和亚太地区的新兴国家由于医疗基础设施的改善和意识的提高而占据有利的地位，显示出成长潜力。儘管面临诊断设施有限和治疗成本高昂等挑战，但远端医疗和远端监测解决方案的整合正在促进扩大甲状腺护理的覆盖范围，特别是在服务不足的地区。儘管这些障碍可能会阻碍成长，但全球甲状腺疾病治疗市场的预期轨迹表明其具有弹性并持续扩张。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

AbbVie Inc.（United States）
Merck & Co., Inc.（United States）
Eli Lilly and Company（United States）
Abbott Laboratories（United States）
Sanofi（France）
Boehringer Ingelheim（Germany）
Takeda Pharmaceutical Company Limited（Japan）
Bayer AG（Germany）
Mylan NV（Netherlands）
Fresenius Kabi AG（Germany）
Bristol-Myers Squibb Company（United States）
Novartis International AG（Switzerland）
GlaxoSmithKline plc（United Kingdom）
Johnson & Johnson（United States）
Amgen Inc.（United States）
AstraZeneca（United Kingdom）
Cipla Ltd.（India）
Pfizer Inc.（United States）
Sun Pharmaceutical Industries Ltd.（India）
Teva Pharmaceutical Industries Ltd.（Israel）

简介目录

Product Code: SQMIG35J2083

Global Thyroid Gland Disorders Treatment Market size was valued at USD 2.37 billion in 2022 and is poised to grow from USD 2.45 billion in 2023 to USD 3.14 billion by 2031, growing at a CAGR of 3.17% in the forecast period (2024-2031).

The global market for treating thyroid gland disorders has experienced significant growth in recent years, largely driven by the increasing prevalence of conditions like hyperthyroidism worldwide. Factors such as aging populations, advancements in medical technology, and a growing emphasis on early diagnosis and treatment have contributed to this expansion. Furthermore, the introduction of new customized medicine techniques and targeted medications tailored to specific thyroid issues has enriched the market landscape. While North America and Europe currently dominate this market due to higher rates of thyroid disorders and healthcare expenditures, emerging economies in Latin America and Asia-Pacific exhibit promising growth potential due to improving healthcare infrastructure and rising awareness. Despite challenges such as limited diagnostic facilities and high therapy costs, the integration of telemedicine and remote monitoring solutions, particularly in underserved areas, has facilitated greater access to thyroid care. Although these obstacles may hinder growth, the projected trajectory of the global thyroid gland disorders treatment market suggests resilience and continued expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segmental Analysis

Market segmentation based on treatment methods includes medication, radioiodine therapy, thyroidectomy, and alternative therapies. When the market is divided based on end-users, it includes hospitals, clinics, and retail pharmacies. Geographically, the market can be divided into North America, Europe, Asia-Pacific, and the rest of the world.

Drivers of the Thyroid Gland Disorders Treatment Market

The global market for treating thyroid disorders is experiencing notable growth, propelled by the escalating prevalence of conditions such as hyperthyroidism, hypothyroidism, and thyroid cancer worldwide. Factors contributing to this rise include heightened mental stressors impacting lifestyles and environmental influences. Consequently, there has been a surge in demand for treatments targeting thyroid gland issues. Advancements in medical research and technology have significantly enriched the market with a plethora of innovative therapy options, including novel drugs, targeted therapies, and minimally invasive surgical procedures.

Restraints in the Thyroid Gland Disorders Treatment Market

Despite these advancements, challenges such as the exorbitant cost of medications and treatments, particularly for long-term therapies, pose a significant barrier to accessibility, especially for patients in underserved areas with limited healthcare access or inadequate insurance coverage. Moreover, the scarcity of diagnostic facilities and low awareness about thyroid health in certain regions hinder early detection and treatment initiation, potentially impacting patient outcomes and survival rates.

Market Trends of the Thyroid Gland Disorders Treatment Market

Market trends reflect a proactive response to these challenges, with increased investment in research and development by pharmaceutical companies to develop more effective and affordable treatment options. Additionally, the market is witnessing a growing emphasis on diversifying treatment modalities in response to the rising incidence of thyroid disorders globally, driven by lifestyle changes, improved diagnostic capabilities, and dietary shifts. As a result, demand for surgical interventions, medications, and radioactive iodine therapy is on the rise, underscoring the expanding scope of the thyroid disorder treatment market.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Thyroid Gland Disorders Treatment Market by Treatment Methods

Market Overview
Medication
Radioiodine therapy
Thyroidectomy
and Alternative therapies

Global Thyroid Gland Disorders Treatment Market by End-users

Market Overview
Hospitals
Clinics
and Retail Pharmacies

Global Thyroid Gland Disorders Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States))
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany))
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments